

Vanderbilt Stem Cell Transplant and Cellular Therapy Symposium

Saturday, August 29, 2026

7:00 AM - 8:00 AM

REGISTRATION & BREAKFAST

8:00 AM - 8:15 AM

WELCOME AND OPENING STATEMENTS

Ben Ho Park, MD, PhD

Director, Vanderbilt-Ingram Cancer Center

Benjamin F. Byrd, Jr. Chair in Oncology

Professor of Medicine, Division of Hematology/Oncology

Vanderbilt Health

Karen Proctor, RN, MSN, NE-BC

Administrative Director, Nursing

Hematology/Stem Cell Transplant Program

Vanderbilt Ingram Cancer Center

8:15 AM - 8:50 AM

Strategies to Improve Lymphoma CAR19 Efficacy

Dr. David Miklos

James and Katherine Lau Professor

Chief of Stanford BMT and Cell Therapy Program

8:55 AM - 9:10 AM

Cellular Engineering Strategies to Overcome the Tumor Microenvironment

Dr. Andrew Jallouk

Assistant Professor of Medicine

Division of Hematology and Oncology

Vanderbilt University School of Medicine

Vanderbilt-Ingram Cancer Center

9:15 AM - 9:30 AM

Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial

Dr. Bhagi Dholaria

Associate Professor of Medicine

Division of Hematology and Oncology

Vanderbilt University School of Medicine

Vanderbilt-Ingram Cancer Center

9:30 AM - 9:45 AM

COFFEE BREAK

9:45 AM - 10:20 AM	CARs in solid tumors “Bench to bedside” Dr. Daniel Lee Associate Professor - UVA Children's Director of Pediatric Hematopoietic Stem Cell Transplantation and Immunotherapy.
10:25 AM - 10:40 AM	Germline mutations in heme malignancies Dr. Kate Fedorov Assistant Professor of Medicine Division of Hematology and Medical Oncology Vanderbilt University School of Medicine Vanderbilt-Ingram Cancer Center
10:45 AM - 11:00 AM	Prevention of post-transplant relapse “Intercept Clinic” Dr. Somdeb Ball, MD Assistant Professor of Medicine Division of Hematology and Oncology Vanderbilt University School of Medicine Vanderbilt-Ingram Cancer Center
11:00 AM - 12:00 PM	LUNCH
12:00 PM - 12:35 PM	Myeloma Novel Therapies Dr. Ajay Nooka Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine Director of the Myeloma Program
12:40 PM - 12:55 PM	Bispecifics vs CAR T-cell therapy in Multiple Myeloma Dr. Eden Biltibo Assistant Professor of Medicine Division of Hematology and Oncology Vanderbilt University School of Medicine Vanderbilt-Ingram Cancer Center
1:00 PM - 1:15 PM	Approaches to Treating Relapsed and Refractory AL Amyloidosis Dr. Salyka Sengsayadeth Associate Professor of Medicine Division of Hematology and Oncology Vanderbilt University School of Medicine Vanderbilt-Ingram Cancer Center

1:20 PM - 1:55 PM	Fratricide, Aplasia, and Efficacy: The CAR T Balancing Act in T cell Malignancies Dr. Sattva Neelapu Professor and Deputy Chair Department of Lymphoma and Myeloma The University of Texas M.D. Anderson Cancer Center
1:55 PM - 2:10 PM	COFFEE BREAK
2:10 PM - 2:25 PM	Current Transplant Strategies in Bone Marrow Failure Dr. Jim Connelly Assistant Professor of Pediatrics, Hematology/Oncology Vanderbilt University School of Medicine Vanderbilt-Ingram Cancer Center
2:30 PM – 2:45 PM	Clonal Hematopoiesis in Sickle Cell Disease-clinical implications Dr. Ashwin Kishtagari Assistant Professor of Medicine Division of Hematology & Oncology Vanderbilt University Medical Center Vanderbilt-Ingram Cancer Center
2:50 PM - 3:10 PM	PANEL & QUESTIONS: State of the Art Therapy in CAR T cells Dr. Sattva Neelapu Dr. David Miklos Dr. Daniel Lee Dr. Oluwole Olalekan Nancy Long, MSN, APRN, AGACNP-BC
3:15 PM – 3:45 PM	PANEL & QUESTIONS: State of the Art Stem Cell Therapy for malignant and Non-Malignant Diseases Dr. Adetola Kassim Dr. Bipin Savani Dr. Salyka Sengsayadeth Dr. Jim Connelly
3:50 PM - 4:00 PM	CLOSING REMARKS